233 related articles for article (PubMed ID: 12605365)
1. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
2. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
[TBL] [Abstract][Full Text] [Related]
3. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.
Lai R; Medeiros LJ; Wilson CS; Sun NC; Koo C; McCourty A; Brynes RK
Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185
[TBL] [Abstract][Full Text] [Related]
4. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
Skomedal H; Kristensen GB; Lie AK; Holm R
Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
9. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
Mouriaux F; Maurage CA; Labalette P; Sablonnière B; Malecaze F; Darbon JM
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2837-43. PubMed ID: 10967035
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
12. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis.
Hoos A; Nissan A; Stojadinovic A; Shia J; Hedvat CV; Leung DH; Paty PB; Klimstra D; Cordon-Cardo C; Wong WD
Clin Cancer Res; 2002 Dec; 8(12):3841-9. PubMed ID: 12473598
[TBL] [Abstract][Full Text] [Related]
13. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
[TBL] [Abstract][Full Text] [Related]
16. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
